Skip to main content

Home/ Health affairs/ Group items tagged Independent-Pharmacies-for-Sale-Midlands

Rss Feed Group items tagged

pharmacybiz

Sukh Gill Acquires Wednesbury Pharmacy - 0 views

  •  
    Wednesbury Pharmacy in Sandwell, West Midlands has been purchased by Sukh Gill of Sodaskill Limited who already owns a community pharmacy in the area, Specialist business property adviser, Christie & Co, announced on Thursday (1st January) Located in the Friar Park area of Wednesbury, this pharmacy dispenses an average of 7,600 items per month and follows standard opening hours. It was owned by Enimed Limited for over five years before it was brought to market last year. The ownership of the business was changed to Gill, who already owns Friar Park Chemist just a few doors up the road, following a confidential 'off-market' sales process at Christie & Co. Carl Steer, Director - Medical at Christie & Co, said, "It is always pleasing to complete a sale, but when you have been able to perform to the brief a client dictates, all the better.
pharmacybiz

Ian Adamson : Maxwellia appoints s Strategic Advisor - 0 views

  •  
    Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist. Ian brings over 30 years' international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals Ltd. Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl. Ian's appointment follows the landmark reclassification of the progestogen only pill by the MHRA, a change spearheaded by Maxwellia, and the company's subsequent launch of its first product Lovima in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia's new pharmacy brand, Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone.
1 - 2 of 2
Showing 20 items per page